Additional 20% increase in production effect with vaccine syringes with minimal residual special technology applied
US FDA approval, in front of export, inundated 260 million supply requests from 20 countries
[바이오타임즈] Poonglim Pharmatech (CEO Hee-min Jo), a medical device manufacturer, is attracting attention, with related stocks rising at the same time ahead of the domestic vaccination of the Corona 19 vaccine next week.
The company is approved by the Ministry of Food and Drug Safety and produces more than 10 million syringes for the Corona 19 vaccine per month. In addition, it is known that it is planning to proceed with export consultations with US pharmaceutical companies according to the approval of the US FDA.
Yesterday, President Moon Jae-in visited Poonglim Pharmatech and encouraged him to say, “I am ahead of the corona vaccine vaccination starting next week.
Recently, there is a worldwide shortage of syringes for the COVID-19 vaccine, and the syringes for the COVID-19 vaccine developed by Poonglim Pharmatech requested more than 260 million supplies from more than 20 countries around the world, including Pfizer and the United States and Japan. Are receiving.
What kind of technology is hiding in the syringe for the Corona 19 vaccine developed by Poonglim Pharmatech, so is it receiving requests for supply from many countries?
Founded in 1999, Poonglim Pharmatech has been manufacturing, producing, and importing medical devices, such as glass syringes and vials (glass containers for storage), mainly used by pharmaceutical companies and hospitals.
The company has developed a special syringe with minimal residual type (LDS/Low Dead pace or LDV/Low Dead Volume) technology to be used for COVID-19 vaccination. In general syringes, the remaining amount after injection of the injection solution per minute is 84 microliters (µl) or more, but Poonglim Pharmatech’s LDV syringe has been minimized to 4 microliters. In other words, it minimizes the amount of injection remaining in the syringe after drug administration.
As a result, with a general syringe, you can only inject up to 5 times per bottle of Corona 19 vaccine, and Poonglim Pharmatech’s LDV syringe can inject more than 6 times per bottle. If Poonglim Pharmatech’s syringe is used for vaccination, there is an effect of increasing the production of the Corona 19 vaccine by an additional 20%. This means that if Korea receives 10 million vaccines, it can inoculate 12 million people.
Earlier, there was news that Japan failed to increase production of vaccine syringes and delivered 12 million Pfizer vaccines.
In addition, the’safety guard sterilization needle’, which secures the safety of medical personnel and patients by combining a contaminated needle after injection with a safety guard, was also successfully commercialized.
Poonglim Pharmatech also boosted syringe productivity with the help of the Small and Medium Venture Business Department and Samsung Electronics. Samsung Electronics is supporting the construction of a win-win smart factory for small and medium-sized businesses with the Ministry of Medium and Medium Business. Poonglim Pharmatech also supported the production of syringe automatic assembly facilities using ultra-precision mold and injection technology. As a result, a mass production system was established that can produce more than 10 million units per month, which is 2.5 times that of Poonglim Pharmatech’s 4 million units per month.
Samsung is also known to have helped to quickly approve the US FDA for Poonglim Pharmatech’s LDV syringes. Poonglim Pharmatech received final approval for LDS syringes from the FDA in 56 days with the help of Samsung.
Currently, Poonglim Pharmatech is receiving inquiries for supply of 180 million vaccine syringes from the US and 80 million vaccine syringes from Japan.
Including this, the company plans to additionally establish a production system of more than 10 million vaccine syringes per month in the 3rd factory (new factory) currently being built in order to meet the influx of orders in 20 countries. Through this, it will be equipped with the world’s largest vaccine syringe supply system with more than 20 million units per month.
In addition, Poonglim Pharmatech plans to provide 127,000 vaccine syringes free of charge to the Korea Centers for Disease Control and Prevention for the health of the public.
Meanwhile, as Poonglim Pharmatech attracted attention with LDV syringes, syringe companies such as Samsung Pharmaceutical, Shinshin Pharmaceutical, Medipost, Raphas, Huons and Innotherapy are emerging as related stocks.
As the Corona 19 vaccine vaccination is in full swing, the Ministry of Mid-term and Mid-term is further promoting the supply of win-win smart factories to 6-7 syringe manufacturers, including Poonglim Pharmatech, Korea Vaccine, and Sungsim Medical.
[바이오타임즈=김수진 기자] [email protected]
Copyright © BioTimes Unauthorized reproduction and redistribution prohibited